HOME >> BIOLOGY >> NEWS
UI Laboratory Develops Procedure To Study DNA Replication

IOWA CITY, Iowa -- A University of Iowa research team has developed a way to isolate replicating deoxyribonucleic acid (DNA) molecules that scientists then can use to examine the replication process under controlled conditions. This advance will allow investigators to better understand DNA replication and may lead to improved therapies for treating diseases such as cancer.

"One of the difficulties with studying the DNA replication process is that there are multiple protein complexes involved, and it is difficult to experimentally dissect individual reactions that are occurring," said Marc Wold, Ph.D., UI associate professor of biochemistry and the project's principal investigator. "Our procedure will allow us to examine these reactions in more detail."

DNA is the genetic material that encodes all components in human cells. Each cell contains more than two meters of DNA. Every time a cell divides, it is necessary to duplicate all of its DNA.

Using DNA derived from the Simian Virus 40 from monkeys, Wold and members of his laboratory let DNA replication start in an extract from human cells. The researchers attach magnetic beads to the DNA molecules and use a magnet to isolate the molecules and associated replication proteins. The researchers can then manipulate the extracted DNA and add specific replication proteins in a controlled manner to understand the mechanics of DNA replication.

"This will mean we can start asking specific questions about the reactions during replication and learn more about the specific roles of replication proteins," Wold said.

The advantage of this system is that it allows separation of the DNA replication process from the synthetic reactions. This separation has been difficult to achieve in previous replication systems.

Using his technique, Wold hopes that his lab and others can begin to understand what causes some cells to mutate. DNA replication is a complex process that is very accurate and highly regulate
'"/>

Contact: Jennifer Cronin
jennifer-cronin@uiowa.edu
319-335-9917
University of Iowa
30-Mar-1999


Page: 1 2

Related biology news :

1. Laboratory grows world record length carbon nanotube
2. Story tips from the Department of Energys Oak Ridge National Laboratory, September 2004
3. Pacific Northwest National Laboratory gets $10 million from NIH to build virtual lung
4. Story tips from the Department of Energys Oak Ridge National Laboratory, August 2004
5. Story tips from the Department of Energys Oak Ridge National Laboratory, July 2004
6. Oak Ridge National Laboratory to develop DOE leadership-class computing capability for science
7. Institute for Systems Biology, Pacific Northwest National Laboratory announce collaboration
8. Story tips from the Department of Energys Oak Ridge National Laboratory, April 2004
9. Laboratory rat gene sequencing completed
10. ORNL earns four Federal Laboratory Consortium awards
11. Story tips from the Department of Energys Oak Ridge National Laboratory, February 2004

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Laboratory Develops Procedure Study DNA Replication

(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
(Date:5/11/2015)... Ohio , May 11, 2015  Through a well-rounded ... Ohio had a strong showing at AUVSI,s Unmanned ... These representatives of Ohio,s UAS industry ... and abroad from all points along the UAS ecosystem. ... Development Coalition,s (DDC) Vice President for Aerospace Rich Knoll ...
(Date:5/10/2015)... GOTHENBURG, Sweden , May 11, 2015 ... touch fingerprint sensors FPC1025 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... the sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + 1 000 ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
(Date:5/21/2015)... Specialty Pharmacy Times has completed its ... BPA Worldwide as a business publication member. As ... for Specialty Pharmacy Times based on business/distribution, demographics ... member of BPA Worldwide, Specialty Pharmacy Times shows ... the most reliable, unequaled data,” said Chris Hennessy, ...
(Date:5/21/2015)... 21, 2015  The EveryLife Foundation for Rare ... and Amy Klobuchar (D-MN) today for ... & Treatments, or OPEN ACT. Supported ... organizations, this bipartisan legislation promises to rapidly bring ... rare disease patients by incentivizing drug makers to ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Veolia’s environmental monitoring technology division, ... distribution agreement with VWR to distribute TECTA™ B16, ... than 160 years of experience, VWR, a leading ... and production facilities, has cultivated a value proposition ... to enable science. Endetec’s TECTA™ B16, combines ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
Cached News: